Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Healthcare Today.
Press releases published on July 29, 2025
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
GlobeNewswire
·
July 29, 2025
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented …
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
GlobeNewswire
·
July 29, 2025
PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results on Monday, August 4, 2025, prior to …
Microbix Launches QUANTDx™ Characterized Reference Materials
GlobeNewswire
·
July 29, 2025
MISSISSAUGA, Ontario, July 29, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line of well- …
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
July 29, 2025
FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company …
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
GlobeNewswire
·
July 29, 2025
– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – Over 800 patients enrolled across the LUGANO and …
Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease
GlobeNewswire
·
July 29, 2025
MENLO PARK, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve …
Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke
GlobeNewswire
·
July 29, 2025
The Phase 3 clinical trial of sovateltide, RESPECT-ETB, is expected to enroll over 500 patients with a primary endpoint of proportion of patients demonstrating functional independence at 90 days and is being conducted under a Special Protocol Assessment ( …
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025
GlobeNewswire
·
July 29, 2025
NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, …
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025
GlobeNewswire
·
July 29, 2025
BEDFORD, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, …
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
GlobeNewswire
·
July 29, 2025
Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be published on the …
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
GlobeNewswire
·
July 29, 2025
― Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious adverse events (SAEs) ― ― Observed robust and rapid pan- …
Glucose Health, Inc. (OTC: GLUC) Highlights U.S. Department of Health and Human Services Designation of Key Nutrient Validating Company’s Patent-Pending Nutrition Formulation via CNBC, Fox Business and Bloomberg Television Media Blitz
GlobeNewswire
·
July 29, 2025
BENTONVILLE, Ark., July 29, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a publicly traded consumer healthcare company focused on diabetic nutrition and soluble fiber-based nutrition formulations, today announced the launch of a targeted …
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
GlobeNewswire
·
July 29, 2025
― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatment; 7 of 16 patients achieved absolute HbF levels greater than 20% ― ― Evidence of pan-cellular induction of HbF based on an …
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
GlobeNewswire
·
July 29, 2025
- Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges – - Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 therapy - HUNTSVILLE, …
Meliodays and Celanese Partner for Meliodays’ Development of Hormone-Free Non-Contraceptive IUD designed to Treat Menstrual Pain
GlobeNewswire
·
July 29, 2025
Celanese’s VitalDose® Drug Delivery Platform will enable a long-acting, patient-centric formulation for Meliodays’ IUD design MUNICH, July 29, 2025 (GLOBE NEWSWIRE) -- Meliodays Medical and Celanese Corporation (NYSE: CE) have signed an agreement related …
MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy
GlobeNewswire
·
July 29, 2025
European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD) Designation is paving the way for safer long-term therapy MP1032 has demonstrated ability to preserve muscle …
Concept Life Sciences & Fios Genomics Partner to Enhance Complex Data Analysis in Drug Discovery
GlobeNewswire
·
July 29, 2025
CHAPEL-EN-LE-FRITH and EDINBURGH, United Kingdom, July 29, 2025 (GLOBE NEWSWIRE) -- Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences industry, today announced a strategic partnership with Edinburgh- …
LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy
GlobeNewswire
·
July 29, 2025
Galway, London, 29 July 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces a grant of €12 million has been awarded from Ireland’s Disruptive Technologies …
Basilea initiiert Phase-3-Studie mit Antipilzmittel Fosmanogepix bei invasiven Schimmelpilzinfektionen
GlobeNewswire
·
July 29, 2025
Studie zur Evaluierung der Wirksamkeit und Sicherheit von Fosmanogepix bei Erwachsenen mit invasiven Schimmelpilzinfektionen Studienabschluss im 1. Quartal 2028 erwartet Allschwil, 29. Juli 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein …
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
GlobeNewswire
·
July 29, 2025
Study to evaluate the efficacy and safety of fosmanogepix in adults with invasive mold infections Study completion expected in Q1 2028 Allschwil, Switzerland, July 29, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage …